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Abstract
Defective Rhinovirus induced interferon-b and interferon-l production has been reported in bronchial epithelial cells from
asthmatics but the mechanisms of defective interferon induction in asthma are unknown. Virus infection can induce
interferon through Toll like Receptors (TLR)3, TLR7 and TLR8. The role of these TLRs in interferon induction in asthma is
unclear. This objective of this study was to measure the type I and III interferon response to TLR in bronchial epithelial cells
and peripheral blood cells from atopic asthmatics and non-atopic non-asthmatics. Bronchial epithelial cells and peripheral
blood mononuclear cells from atopic asthmatic and non-atopic non-asthmatic subjects were stimulated with agonists to
TLR3, TLR4 & TLRs7–9 and type I and III interferon and pro-inflammatory cytokine, interleukin(IL)-6 and IL-8, responses
assessed. mRNA expression was analysed by qPCR. Interferon proteins were analysed by ELISA. Pro-inflammatory cytokines
were induced by each TLR ligand in both cell types. Ligands to TLR3 and TLR7/8, but not other TLRs, induced interferon-b
and interferon-l in bronchial epithelial cells. The ligand to TLR7/8, but not those to other TLRs, induced only type I
interferons in peripheral blood mononuclear cells. No difference was observed in TLR induced interferon or pro-
inflammatory cytokine production between asthmatic and non-asthmatic subjects from either cell type. TLR3 and TLR7/8,,
stimulation induced interferon in bronchial epithelial cells and peripheral blood mononuclear cells. Interferon induction to
TLR agonists was not observed to be different in asthmatics and non-asthmatics.
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Introduction
Asthma exacerbations are an important cause of morbidity,
mortality and health care costs [1]. The most common precipitant
of asthma exacerbations are respiratory virus infections, particu-
larly rhinoviruses [2,3]. Virus infection results in induction of
antiviral interferons (IFNs), including type I: IFN-a and IFN-b and
type III: IFN-l1 and IFN-l2/3, from airway cells [4] and
defective rhinovirus induced IFN production has been identified in
bronchial epithelial cells (BECs) [5–7], bronchoalveolar lavage
(BAL) cells [5,8] and peripheral blood mononuclear cells (PBMCs)
[9] from asthmatic subjects. The mechanisms causing this
impaired IFN induction in cells from asthmatic subjects are
unknown.
Virus induced IFN production occurs via two groups of pattern
recognition receptors, Toll-like receptors (TLRs) and RNA
helicases [10,11]. Much has been learned in animal models
[12,13] but little is known about mechanisms of induction of IFNs
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in primary cells from humans with asthma. We have previously
reported RIG-I, MDA5 and TLR3 mediate rhinovirus induction
of IFNs in primary human BECs from healthy subjects [14] and
that in BAL cells from asthmatics demonstrating deficient
rhinovirus induced type I IFN production, TLR3, RIG-I and
MDA5 expression was not different from non-asthmatics [8]. All
10 known human TLRs are present on BECs [15], however, with
the exception of the known role for TLR3 in healthy subjects [14],
their role in IFN induction in healthy or asthmatic subjects is
unknown. TLR3, TLR7 and TLR8 have been implicated in
responses to virus infection in animal models [16], TLR3 through
recognition of dsRNA [12] and TLR7 and TLR8 through
recognition of ssRNA and small nucleoside analogues [17].
Most work on TLR function in human asthma has been
performed on PBMCs which are often used by investigators as a
surrogate for airway non-structural cell function. In healthy
subjects IFN-a is induced by stimulation with TLR3, TLR4,
TLR7, TLR8 and TLR9 [18,19] and IFN-b is known to be
induced following TLR3 stimulation [20]. TLR7 stimulation is
known to induce type III IFN in PBMCs [21] and reduced TLR7-
ligand induced OAS and MxA mRNA expression and CXCL10/
IP-10 protein production has been reported in PBMCs from
adolescent asthmatic compared with healthy subjects [22].
However, other than TLR7, little is known about the TLRs
involved in induction of type III IFNs in PBMCs and the
functional role of other TLRs in PBMCs from asthmatic subjects is
also uncertain. In addition to increased susceptibility to respiratory
virus infection, asthmatics have increased carriage of atypical
bacteria [23,24] and increased susceptibility to invasive pneumo-
coccal disease [25–27]. TLR4 and TLR9 recognise products of
bacterial infection and little is known about human primary BEC
IFN responses to TLR4 and TLR9 ligands in normal healthy
subjects or in asthmatic subjects.
This study aimed to characterise the type I and III IFN and pro-
inflammatory cytokine responses to TLR3, TLR4, TLR7, TLR8
and TLR9 stimulation in primary human BECs and PBMCs in
healthy normal individuals and atopic asthmatic subjects.
Materials and Methods
Ethics Statement
The study was approved by the St. Mary’s Hospital Ethics
Committee. Reference 07/Q0403/20.
Methods
Primary human BECs were successfully obtained from 10
asthmatics and 9 non-asthmatic and PBMCs from 19 asthmatics
and 17 non-asthmatics. Asthma and atopy was defined as
previously described [8]. Smokers and subjects who had had
exacerbations or respiratory tract infections in the preceding 6
weeks were excluded. Non-asthmatics had no relevant medical
history, no bronchial hyperresponsiveness and were non-atopic.
The study was approved by the St. Mary’s Hospital Ethics
Committee. All subjects gave written informed consent.
BEC and PBMC Isolation and Processing
BECs were obtained by fibre-optic bronchoscopy using a
Keymed BF260 bronchoscope (Olympus, UK) and 5 mm
sheathed endobronchial brushes (Olympus BC-202D-5010) ac-
cording to BTS guidelines. Freshly obtained BECs were then
seeded into bronchial epithelial growth medium (BEBM, Lonza)
further supplemented with 5,000 units penicillin and 5000 mg
streptomycin. Epithelial origin of cells was confirmed by cytoker-
atin 19 staining and cell culture was performed as previously
described [7]. PBMCs were isolated from fresh whole blood and
processed as previously described [4].
Figure 1. TLR3 induced type I and III IFN in HBECs. Figures depict IFN-b protein [A], IFN-b mRNA [B], IFN-l protein [C], IFN-l1 mRNA [D] and
IFN-l2/3 mRNA [E] at 8 h following Poly I:C stimulation. Squares represent asthmatics and circles represent non-asthmatics. * = p,0.05, ** = p,0.01,
*** = p,0.001.
doi:10.1371/journal.pone.0065921.g001
TLRs in Asthma
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TLR Stimulation
TLR3 stimulation was performed with Polyinosinic-Polycy-
tidylic Acid (Poly I:C), TLR4 with Lipopolysaccharide (LPS),
TLR7/8 with Resiquimod (R848), TLR8 with RNA40 complexed
with N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium
methyl-sulphate (DOTAP) (ssRNA) and TLR9 with CpG-ODN.
For doses and source of TLR agonists see Table S1. Doses used
were based on preliminary dose response experiments in
commercially obtained primary bronchial epithelial cells and
PBMCs (see Table S2). As negative controls, cells were treated
with medium alone. Cells were harvested at 8 h, 24 h and 48 h
post TLR stimulation.
RNA Isolation and qPCR
RNA extraction was performed using RNeasy MiniKit (Qiagen,
Hilden, Germany) and used for cDNA synthesis by Omniscript
RT kit (Qiagen). Reactions were analysed using an ABI 7000
TaqMan (ABI Foster City, CA, USA) as previously described [14]
and were normalised to 18 s. Primer and probe sequences are
listed in Table S3.
IFN Protein Measurement
IFN-b (Invitrogen, CA, USA), IFN-a (Invitrogen) and IFN-l
(R&D systems) release were measured by ELISA according to the
manufacturer’s instructions. The sensitivities of each assay were
10 pg/mL.
IL-6 and IL-8 Protein Measurement
Paired antibodies (R&D Systems) were used for IL-6 and IL-8
protein release. The sensitivities of each assay were 15 pg/mL.
Statistical Analysis
Graphpad prism software (version 5.04; GraphPad Software,
San Diego, Ca) was used to perform statistical analysis. Kruskal
Wallis test with Dunn’s correction was used as the majority of data
was not normally distributed. If significant, this was followed by
between group testing with Mann Whitney test. A p-value of
,0.05 was considered significant. Data is presented as medians
unless indicated otherwise.
Results
IFN and Pro-inflammatory Cytokine Induction by TLR
Agonists in Primary Human BECs
BECs were successfully cultured from 10 asthmatic and 9 non-
asthmatic healthy subjects. Clinical characteristics of these
participants are shown in Table S4. To assess which TLRs were
important in IFN induction in bronchial epithelial cells, BECs
were stimulated with agonists to TLR3 (poly I:C), TLR4 (LPS),
TLR7/8 (R848), TLR8 (RNA40 complexed with DOTAP) and
TLR9 (CpG-B-ODN and CPG-C-ODN) and supernatants and
cells were harvested after 8 and 24 hrs. As the major IFN sub-
types induced by virus infection of BECs are IFN-b and IFN-l [4],
investigations were limited to these sub-types. There was no
statistically significant induction of either IFN-b or IFN-l protein
release or mRNA expression following TLR4, TLR8 or TLR9
stimulation at any time point (data not shown).
TLR3 Stimulation Induced Type I and III IFN Protein
Release from Human Primary BECs from Asthmatic and
Healthy Subjects and TLR7/8 Stimulation Induced Type I
IFN Protein in Asthmatics only and Type III IFN Protein
from both Asthmatics and Non- asthmatics
TLR3 stimulation induced significant type I and III IFN in
BECs and induction was greatest at 8 h following stimulation.
IFN-b and IFN-l protein and mRNA were significantly induced
at 8 h in both groups (Figure 1, 24 h not shown). TLR3 induced
type I and III IFN protein and mRNA was not significantly
different between asthmatic and non-asthmatic subjects.
IFN response to TLR7/8 stimulation was most prominent at
24 h and consisted mainly of type III IFN. At 24 h, R848 induced
some IFN-b protein in 4 asthmatic subjects only but did not
Figure 2. TLR7 stimulation induced type I and III IFN in HBECs. Graphs depict IFN-b protein [A], IFN-b mRNA [B], IFN-l protein [C], IFN-l1
mRNA [D] and IFN-l2/3 mRNA [E] at 24 h following stimulation with R848. Squares represent asthmatics, circles represent non-asthmatics.
* = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0065921.g002
TLRs in Asthma
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induce IFN-b mRNA in either group at any time point. In the
same cells at 24 h, R848 induced robust IFN-l protein and
mRNA in both groups (Figure 2, 8 h not shown). No difference
was observed in IFN-l induction between asthmatic and non-
asthmatic subjects.
Stimulation of TLR3, TLR4 and TLRs7–9 Induced Pro-
inflammatory Cytokine (IL-6 and IL-8) Release from BECs
in both Asthmatic and Non-asthmatic Subjects
To confirm the TLR agonists used induced pro-inflammatory
cytokines, IL-6 and IL-8 protein responses to TLR stimulation
were measured. At 8 h IL-6 protein was significantly induced by
poly I:C in both groups and by CpG-B-ODN in asthmatics only.
At 24 h IL-6 protein was significantly induced by R848 in both
groups and by LPS in asthmatics only. There was no significant
IL-6 protein induction with CpG-C-ODN or RNA40 at either
time point (Figure 3).
IL-8 induction in BECs occurred following each of the TLR
agonists used. Significant IL-8 protein induction was seen at 8 h
with poly I:C, CpG-B-ODN and RNA40 in both groups and with
CpG-C-ODN in non-asthmatics. At 24 h both LPS and R848
induced significant IL-8 protein in both groups (Figure 4). There
were no significant differences between asthmatics and non-
asthmatics in induction of IL-6 or IL-8 protein with any of the
TLR ligands at either time point.
IFN and Pro-inflammatory Cytokine Induction by TLR
Agonists in PBMCs
To establish whether induction was similar in BECs and
PBMCs, PBMCs were stimulated with the same TLR agonists
detailed above and IFN protein induction at 8 h, 24 h and 48 h
assessed. IFN protein induction was only observed following
TLR7/8 stimulation in PBMCs, neither type I nor type III IFN
protein was induced with any other TLR ligand at any time point
(data not shown). As no IFN protein induction was observed with
most TLR agonists, IFN mRNA expression was not assessed.
Figure 3. IL-6 induction following TLR stimulation in HBECs. Graphs depict IL-6 production at 8 h following stimulation with PIC [A] and CpG-
B-ODN [B] and at 24 h following R848 [C] and LPS [D]. Squares represent asthmatics, circles represent non-asthmatics. * = p,0.05, ** = p,0.01,
*** = p,0.001.
doi:10.1371/journal.pone.0065921.g003
TLRs in Asthma
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Figure 4. IL-8 induction following TLR stimulation in HBECs. Graphs depict IL-8 production at 8 h following stimulation with Poly I:C [A], CpG-
C-ODN [B], CpG-B-ODN [C] and RNA40 [D] and at 24 h following R848 [E] and LPS [F]. Squares represent asthmatics, circles represent non-asthmatics.
* = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0065921.g004
TLRs in Asthma
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TLR7/8 Stimulation Induced Type I but not type III IFN
Induction and Stimulation of TLR3, TLR4 and TLRs 7–9
Induced Pro-inflammatory Cytokine Release from PBMCs
in both Asthmatics and Non-asthmatics
R848 induced significant IFN-a protein release at 8 h, 24 h and
48 h in both subject groups. IFN-b protein was also induced by
R848 at 8 h and 24 h but not 48 h (Figure 5). IFN-l protein was
not significantly induced at any time point (not shown). No
significant difference in type I IFN induction was observed
between asthmatic and normal subjects following R848 stimula-
tion at any time point.
Stimulation of TLR3, TLR4 and TLRs7–9 Induced Pro-
inflammatory Cytokine Release from PBMCs in both
Asthmatic and Non-asthmatic Subjects
IL-6 protein was induced following poly I:C, LPS and R848 at
8 h, 24 h and 48 h and RNA40 at 8 h and 24 h. Significant IL-6
protein induction was observed at 8 h after stimulation with poly
I:C and R848 in both groups and with LPS and RNA40 in non-
asthmatics only. At 24 h significant induction was observed
following stimulation with poly I:C, R848 and LPS in both
groups and RNA40 in asthmatics only. At 48 h significant
induction of IL-6 protein was observed following stimulation with
poly I:C and R848 in non-asthmatics and LPS in both groups
(Figure 6). No significant induction with either CPG occurred at
any time point (not shown).
IL-8 protein was induced following stimulation with all the TLR
ligands. At 8 h significant IL-8 protein induction was observed in
non-asthmatics following stimulation with poly I:C, R848, LPS
and RNA40. At 24 h significant IL-8 protein induction was
observed following stimulation with poly I:C, LPS, R848 and
RNA40 in both groups and CpG-C-ODN, CpG-B-ODN in non-
asthmatics only. At 48 h IL-8 protein was only significantly
induced by poly I:C in non-asthmatics (Figure 7). No significant
induction was seen with these ligands at other time points (not
shown) and there was no significant difference in IL-6 or IL-8
protein induction between non-asthmatic and asthmatic subjects
with any ligand at any time point.
Discussion
Viruses are responsible for the majority of asthma exacerbations
and can induce type I and III IFNs via TLRs. Type I and III IFN
induction is deficient in asthma. TLR agonists have been identified
as potential therapeutic options for asthma but, despite much work
in animal models, little was previously known about IFN responses
of airway cells to TLR agonists in human asthma. TLR3 and
TLR7/8, were identified as the predominant IFN inducers in
BECs, inducing both type I and III IFN. TLR7/8 was identified as
the predominant inducer of IFN in PBMCs inducing only type I
IFN, a different pattern to that observed in BECs. No difference
was observed in TLR induced IFN or pro-inflammatory cytokine
production between asthmatic and non-asthmatic subjects from
either BECs or PBMCs.
In these experiments ligation of TLR7/8, but not TLR8 alone,
induced robust type III IFN but minimal type I IFN in BECs.
R848 is known to stimulate both TLR7 and TLR8 with TLR7
showing a higher sensitivity to R848 than TLR8 [20] As no
induction was observed following TLR8 stimulation it is possible
that the robust type III IFN response observed is due to
stimulation of TLR7. Although statistically significant IFN-b
protein induction occurred in asthmatic subjects, there was no
mRNA induction and it was only identified in 4 subjects. This
increased responsiveness of R848 in the asthmatic cells is also
surprising in the context of previous reports of reduced TLR7
function in PBMCs in asthma [22] and in pregnancy [21] and
Figure 5. TLR7 stimulation induced type I but not type III IFN in PBMCs. Graphs depict IFN-a protein production 8 h [A], 24 h [B] and 48 h
[C] and IFN-b protein at 8 h [D], 24 h [E] and 48 h [F] post R848 stimulation. Squares represent asthmatics, circles represent non-asthmatics.
* = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0065921.g005
TLRs in Asthma
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should be interpreted with caution. Induction of IFN-l protein
and mRNA was clearly robust suggesting that R848 may be more
important in the production of IFN-l than IFN-b in BECs. It is
currently unclear why R848 stimulation should predominantly
induce type III IFN, over type I IFN, in this cell type.
Due to the invasive nature of obtaining bronchial epithelial cells
PBMCs are often used as a surrogate for airway cells. R848
stimulation in PBMCs produced robust type I IFN induction but
no IFN-l, the opposite pattern to that observed in BECs and
suggests that TLR7 predominantly produces type I IFN in
Figure 6. IL-6 induction following TLR stimulation in PBMCs. Graphs depict IL-6 production at 8 h following stimulation with PIC [A], R848 [D],
LPS [G] and LPS [K], 24 h following PIC [B], R848 [E], LPS [H] and LPS [L] and 48 h following PIC [C], R848 [F], LPS [J] and LPS [M]. Squares represent
asthmatics, circles represent non-asthmatics. * = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0065921.g006
TLRs in Asthma
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PBMCs. In addition to different patterns of IFN subtype
induction, timing of induction was also different. The differences
in IFN induction in PBMCs and BECs from the same individuals
in response to both TLR3 and TLR7/8 agonists highlight that
using PBMCs as a surrogate for BECs may be sub-optimal and
misleading with regard to responses in BECs.
IFN-a induction by PBMCs from healthy individuals has
previously been reported following stimulation with TLR3, TLR4,
TLR7, TLR8 and TLR9 [18,19] and IFN-b following TLR3
Figure 7. IL-8 induction following TLR stimulation in PBMCs. Graphs depict IL-8 production at 8 h following stimulation with PIC [A], R848 [B],
LPS [C] and RNA40 [D], 24 h following PIC [E], R848 [F], CpG-C-ODN [G], CpG-B-ODN [H], LPS [I] and RNA40 [J] and 48 h following PIC [K]. Squares
represent asthmatics, circles represent non-asthmatics. * = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0065921.g007
TLRs in Asthma
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stimulation [20]. Differences exist in the experimental techniques
used in these studies, including the use of pooled, stored PBMCs
[19] and different agonists [18], doses [20] and cell numbers [20]
which may influence the differences in observed findings. Previous
studies also used samples from smaller numbers of individuals and
these discrepant findings further highlight the problems of using
PBMCs to represent airway cell function.
There have now been multiple reports of defective virus induced
IFN induction in various cell types from people with asthma [5–
9,28–31]. As TLRs induce IFN in response to virus infection it was
possible that asthmatics may have had defective TLR function
which may result in deficient IFN induction. The experiments
performed identified that TLR function was similar in these
asthmatic and non-asthmatic subjects, except for the weak but
statistically significant induction of IFN-b protein that was
observed in BECs from asthmatic but not normal subjects.
Despite this, it can be concluded that in the BECs and PBMCs in
this study asthmatic subjects did not have deficient TLR induced
IFN responses when compared to normal subjects. These
experiments were planned at a time when defective IFN induction
in asthma was limited to 4 reports [5,7,28,29], none of which
reported relationships with asthma severity or control. Since
recruitment completed, some evidence has emerged suggesting
that IFN-deficiency may be more profound in more severe active
asthma [8,30]. The asthmatics recruited in this study were well
controlled, median ACQ was 0.59 with good asthma control being
defined as an ACQ score of ,0.75 [32], which may have
influenced the failure to detect defective IFN induction.
In summary, this study investigated the role of TLRs 3, 4 and 7–
9 in type I and type III IFN production in BECs and PBMCs from
asthmatic and healthy non-asthmatic subjects. Stimulation of
TLR3 and TLR7/8, but not TLR4 or 9, induced IFNs in BECs.
No differences were detected in IFN induction between asthmatic
and non-asthmatic subjects following TLR stimulation.
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